About Achilles Therapeutics

Achilles Therapeutics is a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens: protein markers unique to each individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. Targeting multiple clonal neoantigens that are present on all cancer cells, but not on healthy cells, allows individualised treatments to target and destroy tumours without harming healthy tissues.

MANAGEMENT TEAM

Iraj Ali

Chief Executive Officer

View Bio +

Jane Robertson

Chief Medical Officer

View Bio +

Markus Dangl

Chief Scientific Officer

View Bio +

Edward Samuel

SVP Manufacturing

View Bio +

Katy Newton

VP Process Development

View Bio +

Fionnuala Patterson

VP Bioinformatics

View Bio +

Dara Henry

VP Operations & Business Development

View Bio +

Shree Patel

VP Clinical Operations

View Bio +

Liz Elmhirst

Director Intellectual Property

View Bio +

Robert Coutts

Finance Director

View Bio +

Sean Russell

Director Regulatory Affairs

View Bio +

THE FOUNDERS

Professor Karl Peggs

University College London

View Bio +

Professor Mark Lowdell

University College London

View Bio +

Professor Charles Swanton

University College London & Francis Crick Institute

View Bio +

Professor Sergio Quezada

University College London

View Bio +

THE BOARD OF DIRECTORS

Edwin Moses

Chairman

View Bio +

Iraj Ali

Chief Executive Officer

View Bio +

Martin Murphy

Non-Executive Director

View Bio +

Elisa Petris

Non-Executive Director

View Bio +

Professor Karl Peggs

Founder Director

View Bio +

Michael F. Giordano

Non-Executive Director

View Bio +

Ian Walker

Non-Executive Director

View Bio +